204 related articles for article (PubMed ID: 29424538)
1. Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies.
Zajec M; Jacobs JFM; Groenen PJTA; de Kat Angelino CM; Stingl C; Luider TM; De Rijke YB; VanDuijn MM
J Proteome Res; 2018 Mar; 17(3):1326-1333. PubMed ID: 29424538
[TBL] [Abstract][Full Text] [Related]
2. Mass Spectrometry-Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma.
Martins CO; Huet S; Yi SS; Ritorto MS; Landgren O; Dogan A; Chapman JR
J Mol Diagn; 2020 Jul; 22(7):901-911. PubMed ID: 32302778
[TBL] [Abstract][Full Text] [Related]
3. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.
Noori S; Verkleij CPM; Zajec M; Langerhorst P; Bosman PWC; de Rijke YB; Zweegman S; VanDuijn M; Luider T; van de Donk NWCJ; Jacobs JFM
Clin Chem Lab Med; 2021 Nov; 59(12):1963-1971. PubMed ID: 34392637
[TBL] [Abstract][Full Text] [Related]
4. Tracking of low disease burden in multiple myeloma: Using mass spectrometry assays in peripheral blood.
Chapman JR; Thoren KL
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101142. PubMed ID: 32139008
[TBL] [Abstract][Full Text] [Related]
5. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
McCudden C; Axel AE; Slaets D; Dejoie T; Clemens PL; Frans S; Bald J; Plesner T; Jacobs JF; van de Donk NW; Moreau P; Schecter JM; Ahmadi T; Sasser AK
Clin Chem Lab Med; 2016 Jun; 54(6):1095-104. PubMed ID: 27028734
[TBL] [Abstract][Full Text] [Related]
6. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).
van de Donk NW; Otten HG; El Haddad O; Axel A; Sasser AK; Croockewit S; Jacobs JF
Clin Chem Lab Med; 2016 Jun; 54(6):1105-9. PubMed ID: 26812873
[TBL] [Abstract][Full Text] [Related]
7. M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma.
Guan L; Su W; Zhong J; Qiu L
Clin Chim Acta; 2024 Jan; 552():117623. PubMed ID: 37924928
[TBL] [Abstract][Full Text] [Related]
8. Integrating Serum Protein Electrophoresis with Mass Spectrometry, A New Workflow for M-Protein Detection and Quantification.
Zajec M; Jacobs JFM; de Kat Angelino CM; Dekker LJM; Stingl C; Luider TM; De Rijke YB; VanDuijn MM
J Proteome Res; 2020 Jul; 19(7):2845-2853. PubMed ID: 31895568
[TBL] [Abstract][Full Text] [Related]
9. Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease.
Thoren KL
Semin Hematol; 2018 Jan; 55(1):41-43. PubMed ID: 29759153
[TBL] [Abstract][Full Text] [Related]
10. Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay.
Thoren KL; Pianko MJ; Maakaroun Y; Landgren CO; Ramanathan LV
J Appl Lab Med; 2019 Mar; 3(5):857-863. PubMed ID: 31639760
[TBL] [Abstract][Full Text] [Related]
11. M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator.
Wijnands C; Langerhorst P; Noori S; Keizer-Garritsen J; Wessels HJCT; Gloerich J; Bonifay V; Caillon H; Luider TM; van Gool AJ; Dejoie T; VanDuijn MM; Jacobs JFM
Clin Chem Lab Med; 2024 Feb; 62(3):540-550. PubMed ID: 37823394
[TBL] [Abstract][Full Text] [Related]
12. Multiplexed Immunoaffinity Enrichment of Peptides with Anti-peptide Antibodies and Quantification by Stable Isotope Dilution Multiple Reaction Monitoring Mass Spectrometry.
Kuhn E; Carr SA
Methods Mol Biol; 2016; 1410():135-67. PubMed ID: 26867743
[TBL] [Abstract][Full Text] [Related]
13. Detecting monoclonal immunoglobulins in human serum using mass spectrometry.
Mills JR; Barnidge DR; Murray DL
Methods; 2015 Jun; 81():56-65. PubMed ID: 25916620
[TBL] [Abstract][Full Text] [Related]
14. Electrophoretic patterns post daratumumab.
Sheldon J; Wheeler RD; Powles R
Ann Clin Biochem; 2018 Mar; 55(2):299-301. PubMed ID: 28490184
[TBL] [Abstract][Full Text] [Related]
15. Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.
Murata K; McCash SI; Carroll B; Lesokhin AM; Hassoun H; Lendvai N; Korde NS; Mailankody S; Landau HJ; Koehne G; Chung DJ; Giralt SA; Ramanathan LV; Landgren O
Clin Biochem; 2018 Jan; 51():66-71. PubMed ID: 27664535
[TBL] [Abstract][Full Text] [Related]
16. Clearing drug interferences in myeloma treatment using mass spectrometry.
Kohlhagen MC; Mills JR; Willrich MAV; Dasari S; Dispenzieri A; Murray DL
Clin Biochem; 2021 Jun; 92():61-66. PubMed ID: 33691184
[TBL] [Abstract][Full Text] [Related]
17. A sensitive high-resolution mass spectrometry method for quantifying intact M-protein light chains in patients with multiple myeloma.
Muccio S; Hirtz C; Descloux S; Fedeli O; Macé S; Lehmann S; Vialaret J
Clin Chim Acta; 2024 Jan; 552():117634. PubMed ID: 37980975
[TBL] [Abstract][Full Text] [Related]
18. High-Throughput Therapeutic Antibody Interference-Free High-Resolution Mass Spectrometry Assay for Monitoring M-Proteins in Multiple Myeloma.
Santockyte R; Puig O; Zheng N; Ouyang Z; Titsch C; Zhang YJ; Pillutla R; Zeng J
Anal Chem; 2021 Jan; 93(2):834-842. PubMed ID: 33300779
[TBL] [Abstract][Full Text] [Related]
19. A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference.
Mills JR; Kohlhagen MC; Willrich MAV; Kourelis T; Dispenzieri A; Murray DL
Blood; 2018 Aug; 132(6):670-672. PubMed ID: 29891533
[No Abstract] [Full Text] [Related]
20. A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patients.
Chen S; Kiguchi T; Nagata Y; Tamai Y; Ikeda T; Kajiya R; Ono T; Sugiyama D; Nishikawa H; Akatsuka Y
Int J Hematol; 2021 Apr; 113(4):473-479. PubMed ID: 33507526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
